Peramivir trihydrate
Based on 13 publication(s) in Google Scholar
Peramivir trihydrate (RWJ-270201 trihydrate) is a highly potent, selective and orally active influenza virus neuraminidase (NA) inhibitor, with IC50 values ranging from 0.9 to 4.3 nM for nine NA subtypes.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.30%
- CAS No.: 1041434-82-5
- Formule: C15H34N4O7
- Masse moléculaire:382.45
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
MAPK Compound Library
HY-L010
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-COVID-19 Compound Library
HY-L052
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
EMA-Approved Drug Library
HY-L116
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Peramivir trihydrate
More- Nat Commun. 2013:4:2854. [Abstract]
- NPJ Digit Med. 2025 Nov 21;8(1):712. [Abstract]
- Emerg Microbes Infect. 2025 Dec;14(1):2564308. [Abstract]
- Int Immunopharmacol. 2023 Feb:115:109706. [Abstract]
- PLoS Pathog. 2024 Feb 14;20(2):e1011981. [Abstract]
- Sci Rep. 2021 Aug 11;11(1):16293. [Abstract]
- Int J Infect Dis. 2024 Sep:146:107134. [Abstract]
- Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20. [Abstract]
- PLoS One. 2018 Jul 12;13(7):e0200761. [Abstract]
- PLoS One. 2015 Jun 25;10(6):e0131412. [Abstract]
- bioRxiv. 2025 Nov 17:2025.11.17.688839. [Abstract]
- University of Glasgow. 2023.
- Chemosphere. 2017 Feb:169:550-557. [Abstract]
Activité biologique
IC50：0.9-4.3 nM (NA)[2]
Peramivir trihydrate (0.3125-40 μM, 4 h) has nontoxicity to macrophage[1].
Peramivir trihydrate (2-10 μM, 6-12 h) inhibits cytokine release in LPS-induced hPBMCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7
-
Concentration:0.3125 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
-
Incubation Time:4 h
-
Result:Showed no apparent toxicity in the peramivir-treated macrophages at concentrations up to 40 μM.
Peramivir trihydrate (75 mg/kg, i.m., once a day for 7 days) rescued BALB scid mice from lethal challenge with BR/08 in immunocompromised murine models of infuenza B virus infection[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cytokine storm syndrome model mice[1].
-
Dosage:20 mg/kg, 60 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Decreased 8 cytokines including TNF-a, IFN-a, IFN-γ, chemokines (MCP-1), GM-CSF, IL-1β, IL-6 and IL-12. Showed less inflammatory cell infiltrations, mild alveolar thickening and less bleeding points or congestion. Showed significant protective effects to the lung tissues.
Chemical Information
-
CAS No. 1041434-82-5
-
Appearance Solid
-
Masse moléculaire 382.45
-
Formule C15H34N4O7
-
Color White to off-white
-
SMILES
O[C@H]1[C@]([C@H](C(CC)CC)NC(C)=O)([H])[C@H](NC(N)=N)C[C@@H]1C(O)=O.[H]O.[H]O.[H]O
-
Synonyms
RWJ 270201 trihydrate; BCX 1812 trihydrate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. [Abstract]2013:4:2854. PMID: 24326875 -
NPJ Digit Med
Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost. [Abstract]2025 Nov 21;8(1):712. PMID: 41272280 -
Emerg Microbes Infect
Efficient airborne transmission of influenza D virus in ferret models and serological evidence of human exposure in Northeast China. [Abstract]2025 Dec;14(1):2564308. PMID: 41069204 -
Int Immunopharmacol
Lidocaine inhibits influenza a virus replication by up-regulating IFNα4 via TBK1-IRF7 and JNK-AP1 signaling pathways. [Abstract]2023 Feb:115:109706. PMID: 36638664 -
PLoS Pathog
The HN protein of Newcastle disease virus induces cell apoptosis through the induction of lysosomal membrane permeabilization. [Abstract]2024 Feb 14;20(2):e1011981. PMID: 38354122 -
Sci Rep
Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice. [Abstract]2021 Aug 11;11(1):16293. PMID: 34381119 -
Int J Infect Dis
Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. [Abstract]2024 Sep:146:107134. PMID: 38944411 -
Antimicrob Agents Chemother
Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. [Abstract]2020 Jun 23;64(7):e00222-20. PMID: 32312780 -
PLoS One
An easy, rapid, and sensitive method for detection of drug-resistant influenza virus by using a sialidase fluorescent imaging probe, BTP3-Neu5Ac. [Abstract]2018 Jul 12;13(7):e0200761. PMID: 30001430 -
PLoS One
Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan. [Abstract]2015 Jun 25;10(6):e0131412. PMID: 26110817 -
bioRxiv
Inhibiting Glycan Degradation Prevents HIV-Induced Inflammaging and Cognitive Impairment. [Abstract]2025 Nov 17:2025.11.17.688839. PMID: 41332691 -
-
Chemosphere
2017 Feb:169:550-557. PMID: 27898328
Solvant et solubilité
H2O : 5 mg/mL (13.07 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 4.55 mg/mL (11.90 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhang C, et al. Peramivir, an anti-influenza virus drug, exhibits potential anti-cytokine storm effects [J]. Frontiers in Immunology, 2022, 13: 856327. [Content Brief]
[2]. Pascua P N Q, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection [J]. Scientific reports, 2017, 7(1): 7345. [Content Brief]
[3]. Alame M M, et al.. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections [J]. Frontiers in microbiology, 2016, 7: 450. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.6147 mL | 13.0736 mL | 26.1472 mL | 65.3680 mL |
| 5 mM | 0.5229 mL | 2.6147 mL | 5.2294 mL | 13.0736 mL | |
| 10 mM | 0.2615 mL | 1.3074 mL | 2.6147 mL | 6.5368 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Peramivir trihydrate Related Classifications
HY-17015 Related Classifications
Powered by Bioz